



PRESS RELEASE

FOR RELEASE Wednesday, February 3, 2016

For more information, contact:

Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
901-881-8665

arGentis receives U.S Patent for Arthritis Treatment

Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance of US patent No. 9,144,595 for Altered Peptide Ligands (APLs) for treating arthritis. The research supporting this patent was conducted at the University of Tennessee Health Science Center in Memphis, Tennessee and is licensed by arGentis™ from the University of Tennessee Research Foundation. This patent grants the use of this treatment in the US and is based upon the research of doctors Arnold Postlethwaite, Andrew Kang, and Linda Myers at the University of Tennessee Health Science Center in Memphis Tennessee.

Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of the joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. An autoimmune disorder, rheumatoid arthritis occurs when the immune system mistakenly attacks the body's tissues. In addition to causing joint problems, rheumatoid arthritis sometimes can affect other organs of the body — such as the skin, eyes, lungs and blood vessels. Although rheumatoid arthritis can occur at any age, it usually begins after age 40. The disorder is much more common in women than in men. Treatment focuses on controlling symptoms and preventing joint damage.

The arGentis™ treatment, ARG301, utilizes a modified peptide ligand to treat

rheumatoid arthritis. The first in man, Phase I clinical trial, is currently being conducted with results expected in 2016. Dr. Andrew Kang stated “We believe that it will be safe and effective in the treatment of RA patients with less undesirable side effects than current RA treatments.”

arGentis™ Pharmaceuticals, located in Tennessee was established in 2007 to develop pharmaceuticals that address unmet medical needs. The mission of arGentis™ is to develop and commercialize treatments to improve the health and quality of life of the targeted patient groups and provide a fair return to our investors. The current focus is on autoimmune diseases treated primarily by Rheumatologists.